Robust and persistent replication of the genotype 6a hepatitis c virus replicon in cell culture

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2638-2646

  Yu, Mei ^a   Peng, Betty ^a   Chan, Katie ^a   Gong, Ruoyu ^a   Yang, Huiling ^a   Delaney, William ^a   Cheng, Guofeng ^a  

^a Gilead Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 C METHYLADENOSINE; ADENOSINE DERIVATIVE; ANTIVIRUS AGENT; BOCEPREVIR; CILUPREVIR; COMPLEMENTARY DNA; CYCLOPHILIN A; CYCLOSPORIN; DACLATASVIR; FILIBUVIR; GS 9669; KANAMYCIN KINASE; LEDIPASVIR; LUCIFERASE; MK 3281; MK 5172; NEOMYCIN PHOSPHOTRANSFERASE II; NESBUVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; RENILLA LUCIFERIN 2 MONOOXYGENASE; RNA DIRECTED RNA POLYMERASE INHIBITOR; SERINE PROTEINASE INHIBITOR; SOFOSBUVIR; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; VEDROPREVIR;

5' UNTRANSLATED REGION; AMINO ACID SUBSTITUTION; AMINO ACID SYNTHESIS; AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; COLONY FORMATION; CONSENSUS SEQUENCE; CONTROLLED STUDY; ELECTROPORATION; ENCEPHALOMYOCARDITIS VIRUS; GENE FUSION; GENETIC TRANSFECTION; HEPATITIS C VIRUS GENOTYPE 6; HEPATITIS C VIRUS GENOTYPE 6A; HEPATITIS C VIRUS SUBTYPE 1B; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; INTERNAL RIBOSOME ENTRY SITE; LIMIT OF QUANTITATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PERSISTENT VIRUS INFECTION; PLASMID; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; RESTRICTION SITE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; RNA TRANSCRIPTION; SITE DIRECTED MUTAGENESIS; VIRUS MUTATION; VIRUS REPLICATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; PHYSIOLOGY; REPLICON; TUMOR CELL LINE;

CELL LINE, TUMOR; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; REPLICON; VIRUS REPLICATION;

EID: 84898635005     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01780-13     Document Type: Article

References (40)

1. Negro F, Alberti A. 2011. The global health burden of hepatitis C virus infection. Liver Int. 31(Suppl 2):1-3. http://dx.doi.org/10.1111/j.1478-3231. 2011.02537.x.
2. Lavanchy D. 2011. Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 17:107-115. http://dx.doi.org/10.1111/j.1469-0691.2010.03432. x.
3. Ghany MG, Strader DB, Thomas DL, Seeff LB. 2009. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49:1335-1374. http://dx.doi.org/10.1002/hep.22759.
4. Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR, Monto A. 2012. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am. J. Gastroenterol. 107:669-689. http://dx.doi.org/10.1038/ajg.2012.48.
5. Kuiken C, Simmonds P. 2009. Nomenclature and numbering of the hepatitis C virus. Methods Mol. Biol. 510:33-53. http://dx.doi.org/10.1007/978-1-59745-394- 3-4.
6. Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, Dalgard O, Dillion JF, Flisiak R, Forns X, Frankova S, Goldis A, Goulis I, Halota W, Hunyady B, Lagging M, Largen A, Makara M, Manolakopoulos S, Marcellin P, Marinho RT, Pol S, Poynard T, Puoti M, Sagalova O, Sibbel S, Simon K, Wallace C, Young K, Yurdaydin C, Zuckerman E, Negro F, Zeuzem S. 2011. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int. 31(Suppl 2):30-60. http://dx.doi.org/10.1111/j.1478-3231.2011.02539.x.
7. Germer JJ, Mandrekar JN, Bendel JL, Mitchell PS, Yao JD. 2011. Hepatitis C virus genotypes in clinical specimens tested at a national reference testing laboratory in the United States. J. Clin. Microbiol. 49:3040-3043. http://dx.doi.org/10.1128/JCM.00457-11.
8. Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, Amarapurkar D, Chen CH, Dou X, El Khayat H, Elshazly M, Esmat G, Guan R, Han KH, Koike K, Largen A, McCaughan G, Mogawer S, Monis A, Nawaz A, Piratvisuth T, Sanai FM, Sharara AI, Sibbel S, Sood A, Suh DJ, Wallace C, Young K, Negro F. 2011. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 31(Suppl 2):61-80. http://dx.doi.org/10.1111/j.1478-3231.2011. 02540.x.
9. Nguyen NH, Vutien P, Trinh HN, Garcia RT, Nguyen LH, Nguyen HA, Nguyen KK, Nguyen MH. 2010. Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans. Hepatol. Int. 4:523-529. http://dx.doi.org/10.1007/s12072-010-9181-7.
10. Chao DT, Abe K, Nguyen MH. 2011. Systematic review: epidemiology of hepatitis C genotype 6 and its management. Aliment. Pharmacol. Ther. 34: 286-296. http://dx.doi.org/10.1111/j.1365-2036.2011.04714.x.
11. Fung J, Lai CL, Hung I, Young J, Cheng C, Wong D, Yuen MF. 2008. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J. Infect. Dis. 198:808-812. http://dx.doi.org/10.1086/591252.
12. Gane E, Stedman C, Hyland R, Sorensen R, Symonds W, Hindes R, Berrey M. 2012. Once daily GS-7977 plus ribavirin inHCVgenotypes 1-3: the ELECTRON Trial, poster 1113. 47th Annu. Meet. Eur. Assoc. Study Liver.
13. Hassanein T, Nelson DR, Lawitz E, Dieterich D, Jacobson I, Baker C. 2011. PSI-7977 with PEG/RBV elicits rapid declines in HCV RNA in patients with HCV GT-4 and GT-6, abstr 50. HEPDart.
14. Dunford L, Carr MJ, Dean J, Waters A, Nguyen LT, Ta Thi TH, Thi LA, Do HD, Thi TT, Nguyen HT, Diem Do TT, Luu QP, Connell J, Coughlan S, Hall WW, Nguyen Thi LA. 2012. Hepatitis C virus in Vietnam: high prevalence of infection in dialysis and multi-transfused patients involving diverse and novel virus variants. PLoS One 7:e41266. http://dx.doi.org/10.1371/journal.pone.0041266.
15. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965. http://dx.doi.org/10.1016/S0140-6736(01)06102-5.
16. Liverton N. 2010. MK-5172, the 1st HCV protease inhibitor with potent activity against resistance mutations in vitro, abstr 39. 45th Annu. Meet. Eur. Assoc. Study Liver.
17. Scheel TK, Gottwein JM, Mikkelsen LS, Jensen TB, Bukh J. 2011. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-Alpha. Gastroenterology 140:1032-1042. http://dx.doi.org/10.1053/j.gastro.2010.11.036.
18. Bartenschlager R. 2005. The hepatitis C virus replicon system: from basic research to clinical application. J. Hepatol. 43:210-216. http://dx.doi.org/10. 1016/j.jhep.2005.05.013.
19. Blight KJ, McKeating JA, Marcotrigiano J, Rice CM. 2003. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J. Virol. 77:3181-3190. http://dx.doi.org/10.1128/JVI.77.5.3181-3190.2003.
20. Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, Wakita T. 2003. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125:1808-1817. http://dx.doi.org/10.1053/j.gastro. 2003.09.023.
21. Lohmann V, Hoffmann S, Herian U, Penin F, Bartenschlager R. 2003. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J. Virol. 77:3007-3019. http://dx.doi.org/10.1128/JVI.77.5.3007-3019.2003.
22. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113. http://dx.doi.org/10.1126/science.285.5424.110.
23. Blight KJ, Kolykhalov AA, Rice CM. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974. http://dx.doi.org/10.1126/ science.290.5498.1972.
24. Peng B, Yu M, Xu S, Lee YJ, Tian Y, Yang H, Chan K, Mo H, McHutchison J, Delaney W, Cheng G. 2013. Development of robust hepatitis C virus genotype 4 subgenomic replicons. Gastroenterology 144: 59-61. http://dx.doi.org/10.1053/j. gastro.2012.09.033.
25. Saeed M, Gondeau C, Hmwe S, Yokokawa H, Date T, Suzuki T, Kato T, Maurel P, Wakita T. 2013. Replication of hepatitis C virus genotype 3a in cultured cells. Gastroenterology 144:56-58. http://dx.doi.org/10.1053/j.gastro.2012.09. 017.
26. Saeed M, Scheel TK, Gottwein JM, Marukian S, Dustin LB, Bukh J, Rice CM. 2012. Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells. Antimicrob. Agents Chemother. 56: 5365-5373. http://dx.doi.org/10.1128/AAC.01256-12.
27. Friebe P, Boudet J, Simorre JP, Bartenschlager R. 2005. Kissing-loop interaction in the 3= end of the hepatitis C virus genome essential for RNA replication. J. Virol. 79:380-392. http://dx.doi.org/10.1128/JVI.79.1.380-392. 2005.
28. Robinson M, Yang H, Sun SC, Peng B, Tian Y, Pagratis N, Greenstein AE, Delaney WE. 2010. Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a. Antimicrob. Agents Chemother. 54:3099-3106. http://dx.doi.org/10.1128/AAC.00289-10.
29. Cheng G, Chan K, Yang H, Corsa A, Pokrovskii M, Paulson M, Bahador G, Zhong W, Delaney W. 2011. Selection of clinically relevant protease inhibitor-resistant viruses using the genotype 2a hepatitis C virus infection system. Antimicrob. Agents Chemother. 55:2197-2205. http://dx.doi.org/10.1128/ AAC.01382-10.
30. Link JO, Taylor JG, Xu L, Mitchell M, Guo H, Liu H, Kato D, Kirschberg T, Sun J, Squires N, Parrish J, Keller T, Yang ZY, Yang C, Matles M, Wang Y, Wang K, Cheng G, Tian Y, Mogalian E, Mondou E, Cornpropst M, Perry J, Desai MC. 11 December 2013. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J. Med. Chem. http://dx.doi.org/10.1021/jm401499g.
31. Shih IH, Vliegen I, Peng B, Yang H, Hebner C, Paeshuyse J, Purstinger G, Fenaux M, Tian Y, Mabery E, Qi X, Bahador G, Paulson M, Lehman LS, Bondy S, Tse W, Reiser H, Lee WA, Schmitz U, Neyts J, Zhong W. 2011. Mechanistic characterization of GS-9190 (tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase. Antimicrob. Agents Chemother. 55:4196-4203. http://dx.doi.org/10.1128/AAC.00307-11.
32. Sheng XC, Appleby T, Butler T, Cai R, Chen X, Cho A, Clarke MO, Cottell J, Delaney WE, Doerffler E, Link J, Ji M, Pakdaman R, Pyun HJ, Wu Q, Xu J, Kim CU. 2012. Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease. Bioorg. Med. Chem. Lett. 22: 2629-2634. http://dx.doi.org/10. 1016/j.bmcl.2012.01.017.
33. Fenaux M, Eng Leavitt SSA, Lee YJ, Mabery EM, Tian Y, Byun D, Canales E, Clarke MO, Doerffler E, Lazerwith SE, Lew W, Liu Q, Mertzman M, Morganelli P, Xu L, Ye H, Zhang J, Matles M, Murray BP, Mwangi J, Hashash A, Krawczyk SH, Bidgood AM, Appleby TC, Watkins WJ. 2013. Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob. Agents Chemother. 57:804-810. http://dx.doi.org/10.1128/AAC.02052- 12.
34. Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, Reddy PG, Ross BS, Wang P, Zhang HR, Bansal S, Espiritu C, Keilman M, Lam AM, Steuer HM, Niu C, Otto MJ, Furman PA. 2010. Discovery of a beta-D-2=-deoxy-2=-Alpha-fluoro- 2=-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J. Med. Chem. 53:7202-7218. http://dx.doi.org/10.1021/ jm100863x.
35. Friebe P, Lohmann V, Krieger N, Bartenschlager R. 2001. Sequences in the 5= nontranslated region of hepatitis C virus required for RNA replication. J. Virol. 75:12047-12057. http://dx.doi.org/10.1128/JVI.75.24.12047-12057.2001.
36. Sumpter R, Jr, Loo YM, Foy E, Li K, Yoneyama M, Fujita T, Lemon SM, Gale M, Jr. 2005. Regulating intracellular antiviral defense and permis-siveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J. Virol. 79:2689-2699. http://dx.doi.org/10.1128/JVI.79.5.2689-2699.2005.
37. Yu M, Corsa AC, Xu S, Peng B, Gong R, Lee YJ, Chan K, Mo H, Delaney W, IV, Cheng G. 2013. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons. Antiviral Res. 100:439-445. http://dx.doi.org/10.1016/j.antiviral.2013.08.018.
38. Kim JL, Morgenstern KA, Griffith JP, Dwyer MD, Thomson JA, Murcko MA, Lin C, Caron PR. 1998. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure 6:89-100. http://dx.doi.org/10.1016/S0969-2126(98)00010-0.
39. Yao N, Reichert P, Taremi SS, Prosise WW, Weber PC. 1999. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 7:1353-1363. http://dx.doi.org/10.1016/S0969-2126(00)80025-8.
40. Herlihy KJ, Graham JP, Kumpf R, Patick AK, Duggal R, Shi ST. 2008. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors. Antimicrob. Agents Chemother. 52:3523-3531. http://dx.doi.org/10.1128/AAC.00533-08.